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Abstract. Murine cytomegalovirus (MCMV) encodes several genes which products interact with MHC 
class I molecules (MHC-I) in the secretory pathway to evade antigen presentation. The product of 
MCMV-m06 gene associates with nascent MHC-I proteins and redirects them into lysosomes for degrada-
tion. This report will demonstrate that MCMV-m06 protein is retained in perinuclear early endosomes to-
gether with internalized MHC-I molecules. Since we were not able to capture the MCMV-m06 protein on 
the cell surface, our data suggests that the MCMV-m06 protein is transported from the Golgi into early 
endosomal intermediates prior to their maturation into multivesicular endosomes and lysosomes. In NIH 
3T3 cells with the transfected m06 gene, the endosomal localization of the m06 protein was not observed, 
suggesting that another MCMV function remodels the route of m06 trafficking from the Golgi towards 
late endosomes. (doi: 10.5562/cca1816)  




Upon entering the host cell, many viruses attempt to 
hide from detection by the host immune response, 
whereas infected cells activate the mechanism of anti-
gen presentation in order to display the presence of a 
virus on the cell surface. For this purpose, viral peptides 
are presented on the cell surface in the complex with the 
Major Histocompatibility Class I molecules (MHC-I). 
Cell surface MHC-I molecules are trimoleculear com-
plexes of 45 kDa transmembrane heavy chains, 12 kDa 
β2-microglobulin (β2-m) and endogenously generated 
viral peptides.1 CD8+ lymphocytes recognize this com-
plex and trigger the signal of activation which ultimate-
ly destroys virus-infected cells.2 
Murine cytomegalovirus (MCMV), a member of 
the herpesvirus family, encodes several proteins which 
target the MHC-I trafficking in the secretory pathway 
and therefore interfere with the antigen presentation 
mechanism. The MCMV-m152 protein associates with 
newly synthesized MHC-I proteins and arrests them 
within the endoplasmic reticulum (ER)/endoplasmic-
reticulum-Golgi-intermediate (ERGIC) compartment.3,4 
MCMV-m06 early protein also binds the nascent and 
properly folded MHC-I molecules in the ER, but the 
m06/MHC-I complex is transported out of the ER into 
the Golgi and redirected from its route to the cell sur-
face towards lysosomes for degradation.5 The MCMV-
m04 protein associates with nascent MHC-I complexes 
in the ER and alters their functioning at the cell sur-
face.6,7 These proteins are usually referred to as 
immunevasins.6,7 In addition, we have recently de-
scribed the MCMV function which efficiently down-
regulates the cell surface resident MHC-I molecules.8 
Transport of proteins from the biosynthetic path-
way involves their sorting in the trans-Golgi network 
(TGN) and their delivery either directly to the cell sur-
face or to the endosomal compartments.9 Upon uptake, 
plasma membrane proteins enter into the endocytic 
pathway, a complex of dynamic membrane structures 
which represent functionally and physically distinct 
compartments with a number of distinct stations.10 The 
central sorting station are early endosomes which either 
redirect internalized cargo proteins into late endo-
somes/lysosomes for degradation or incorporate cargo 
proteins into recycling tubular endosomes which 
transport them back to the plasma membrane.11 Early 
endosomes also sort the newly synthesized proteins 
arriving directly from TGN, like major late endosomal 
and lysosomal membrane proteins (LAMPs), and their 
missorting to the cell surface if occur, is corrected by 
rapid endocytic uptake from the plasma membrane. 
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Fully conformed MHC-I proteins are constitutive-
ly internalized from the cell surface into endosomal 
carriers via the Arf6-associated clathrin-independent 
pathway.12–18 Upon internalization, MHC-I proteins 
travel along the endosomal system and undergo a series 
of sorting events at various stages. Approximately, half 
of internalized MHC-I is sorted into recycling tubular 
endosomes and returned back to the cell surface 16,19,20 
whereas the rest enter the perinuclear vacuolar sorting 
endosomes to be delivered into the degradation route.21 
In infected cells, several viruses interfere with 
functions of the vesicular system and thereby down-
regulate the cell surface expression of MHC-I proteins. 
For instance, the HIV-1 Nef protein activates endocyto-
sis of MHC-I22,23 and reroutes their endosomal traffick-
ing,24 whereas Kaposi’s sarcoma-associated herpesvirus 
proteins K3/K5 accelerate their internalization.25 We 
recently reported on cell surface MHC-I proteins as 
being rapidly internalized into the MCMV infected cells 
due to a mechanism that occurs prior to the expression 
of known immunoevasins.8 Internalized MHC-I proteins 
are arrested and retained in vacuolar sorting endosomes. 
Given that the MCMV-m06 protein associates with the 
nascent MHC-I in the ER and further redirects them 
from the Golgi into late endosomes,5 we performed this 
study to test whether the m06 protein passes through the 
retention endosomes which collect MHC-I proteins 
from the plasma membrane. In this report we demon-
strate that the m06 protein reaches the perinuclear 
endosomal compartment loaded with internalized MHC-
I proteins by a route that does not involve its expression 
at the cell surface. 
 
EXPERIMENTAL 
Cell Lines and Viruses 
Primary murine embryonic fibroblasts (MEFs) were 
generated from BALB/c mice and cultivated in the  
Minimal Essential Medium (MEM) supplemented  
with 5 % (volume fraction) foetal bovine serum (FBS), 
2 mmol dm–3 L-glutamine, 100 mg/ml streptomycin and 
100 U/ml penicillin. All reagents were obtained from 
Gibco (Grand Island, NY). The cells were grown in 
Petri dishes as adherent cell lines and used for infection 
after three in vitro passages when they were 90 % con-
fluent. NIH 3T3 cells were obtained from American 
Typing Culture Collection (ATCC CRL1658) and NIH 
3T3-m06 cells, a cell line transfected with m06,26 were 
kindly provided by Dr. Ulrich H. Koszinowski. For 
infection we used the deletion mutant of MCMV with-
out viral Fc receptor (Δm138-MCMV). The virus was 
propagated on third-passage MEFs and purified by 
sucrose-gradient centrifugation. MEFs were infected 
with 0.5–1 PFU per cell. Cells were incubated for 30 
min with virus at 4 °C. To increase the efficiency of viral 
infection, cells were centrifuged at 500 g for 30 min. 
 
Reagents and Antibodies 
The following monoclonal antibodies (mAbs) were 
used: 34-5-8S (mouse IgG2a, ATCC HB-102) that reacts 
with heavy chain (HC) of H2-Dd, MA-215 (mouse 
IgG2b) that reacts with HC of H2-K
d,27 R17 217.1.3 (rat 
IgG, ATCC TIB 219) that recognizes murine transferrin 
receptor (TfR) and Croma-229 (mouse IgG1, produced 
in our laboratory) that recognizes MCMV-m06 protein.5 
MAbs were used as hybridoma culture supernatant for 
immunofluorescence and flow cytometry or as semi-
purified ascites for immuprecipitation. MAbs to GS28, 
EEA1 and LAMP were from Becton Dickinson & Co 
(San Jose, Calif, USA), Alexa555-cholera-toxin B subu-
nit (CTxB), Alexa555- or Alexa488-conjugated anti mouse 
IgG2a, anti mouse IgG2b, anti mouse IgG1, anti chicken 
IgG, anti rat IgG and FITC-conjugated anti mouse Ig 
were all from Molecular Probes-Invitrogen (Eugene, 
OR, USA). Brefeldin A (BFA) was purchased from 
Sigma-Aldrich Chemie GmbH (Germany). Streptavidin-
peroxidase conjugate was from Roche (Indianapolis, 
USA). Polyclonal antibody to the θ isoform of 14-3-3 
protein is an affinity purified rabbit polyclonal Ab 
raised against a peptide corresponding to amino acids 
229-245 mapping at the carboxy-terminus of 14-3-3 θ of 
rat origin (C-17, Santa Cruz Biotechnology). 
 
Cell Surface Expression and Flow Cytometry 
Infected and uninfected control cells were collected by 
short trypsin treatment, washed in culture medium and 
incubated at 4 °C for 30–60 min with approx. 2 μg/ml 
of primary mAbs reagents in PBS containing 10 mmol 
dm–3 EDTA, Hepes pH = 7.2 and 0.1 % NaN3 and 2 % 
FCS (PBS-A). Unbound Abs were removed by three 
washes with cold PBS-A and the cells were incubated 
for 30 min at 4 °C with FITC-conjugated secondary Ab 
reagents (2 μg/ml) in PBS-A. After three washes with 
PBS-A, cells were analyzed by flow cytometry using 
FACSCalibur flow cytometer (Becton Dickinson & Co, 
San Jose, CA, USA). Dead cells were excluded by 
propidium iodide (1 μg/ml) and a total of 5 000 cells 
was acquired. The fluorescence signal was determined 
as mean fluorescence intensity (MFI) after subtraction 
of background fluorescence (ΔMFI) determined on the 
same cells by incubation with nonreactive mAbs of the 
same isotype and appropriate fluorochrome-conjugated 
secondary reagent. 
 
Immunofluorescence and Confocal Analysis 
Adherent cells, grown in six- or twelve-well tissue culture 
plates on glass coverslips, were washed three times with 
PBS, fixed with 4 % paraformaldehyde (PFA, 20 min 
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at room temperature, r.t.), permeabilized with 0.5 % 
Triton X-100 (10–20 min at r.t.) and incubated with 
fluorochrome-conjugated or un-conjugated primary 
reagents for 60 min at 4 °C. Unbound reagents were 
washed by PBS-A, and cells were either embedded or 
incubated for 60 min at 4 °C with an appropriate 
fluorochrome-conjugated secondary reagent. After the 
three washes in PBS-A, cells were embedded in Mowiol 
(Fluka Chemicals, Germany)-DABCO (Sigma Chemical 
Co., Germany) in PBS containing 50 % glycerol and 
analyzed by Olympus Fluoview FV300 confocal micro-
scope (Olympus Optical Co., Tokyo, Japan) with 
60xPlanApo objective and either 4x or 8x zoom (z axis 
was 0.5 μm). Images were processed by Fluoview, Ver-
sion 4.3 FV 300 (Olympus Optical Co., Tokyo, Japan) 
and Adobe Photoshop (San Jose, CA, USA). To visual-
ize the level of co-localization, 8–10 cells per experi-
mental condition were randomly selected on the same 
cover slip among those which were well spread, show-
ing a well-resolved pattern. Images of single cells were 
acquired at the same magnification, exported in TIFF 
format, and processed by Fluoview, Version 4.3 FV 300 
(Olympus Optical Co.). 
 
Colocalization Analysis 
Quantitative analysis of colocalization was performed as 
described previously.28 We used ImageJ software; uti-
lizing JACoP plugin (http://rsb.info.nih.gov/ij/plugins/ 
track/jacop.html) to calculate Manders’ overlap coeffi-
cients (M1 and M2).29 All experimental and control 
images were acquired using identical imaging settings. 
The best-fit lower threshold to eliminate most of the 
signal background was determined using the threshold 
tool and confirmed by visual inspection. Measures were 
made on at least 5 cells per experimental condition. 
 
Internalization of Cell Surface Molecules 
Internalization was performed on adherent cells grown 
on coverslips. Cells were washed three times with PBS 
and cell surface proteins were labeled with mAb rea-
gents at 4 °C for 60 min. Unbound mAbs were removed 
by the three washes with PBS and internalization was 
performed at 37 °C. Internalized mAbs were visualized 
inside the adherent cells by immunofluorescence after 
short acid wash (1 min, pH = 2.2) prior fixation to re-
move mAbs from the cell surface. 
 
Metabolic labeling 
Cells were incubated for 30 min at 37 °C in methionine-
free MEM (Gibco) and labeled with [35S]methionine 
(Amersham Biosciences) for 2–3 hours pulse at a con-
centration up to 200 μCi (7.4 MBq) ml–1 and chased in 
regular MEM supplemented with nonradioactive methi
onine to final concentration of 1 mmol dm–3. Cytoplas-
mic extracts of labeled cells were prepared in NP-40 
lysis buffer (1 % NP-40, 50 mmol dm–3 Tris/HCl (pH = 
7.6), 5 mmol dm–3 MgCl2) containing 1 mmol dm
–3 
phenylmethylsulfonyl fluoride (PMSF, Sigma Chemi-
cals Co.). Nuclei and cellular debris were removed by 
centrifugation at 14 000 r.p.m. for 20 min, and cellular 
extracts were used for immunoprecipitation. 
 
Immunoprecipitation 
Supernatants of cellular lysates were precleared with  
50 % protein A–Sepharose slurry (Amersham Biosci-
ences) at 4 °C for 30 min. Immunoprecipitation of the 
gp48 (m06) viral protein was performed with ascitic 
fluid of mAbs Croma-229 (3 μl). Immune complexes 
were retrieved with protein A–Sepharose (50 μl of 50 % 
slurry) at 4 °C for 1 hour, eluted at 96 °C by incubation 
with SDS sample buffer [0.125 mol dm–3 Tris/HCl  
(pH = 6.8), 20 % glycerol, 3 % SDS, 2 % β-mercapto-
ethanol, 0.05 % bromphenol blue] and analyzed by 
SDS-PAGE (10 % gel) under reducing conditions. 
 
Gel Electrophoresis and Autoradiography 
SDS-PAGE was performed under reducing conditions. 
Polyacrylamide gels with metabolically labeled proteins 
were exposed to an autoradiography film containing 




The Expression Pattern of m06 Protein in MCMV-
infected Cells 
Expression kinetics of gp48/m06 was determined by 
metabolic labeling of infected fibroblasts in three hour 
intervals followed by immunoprecipitation of m06 pro-
tein from cellular lysates. As shown in Figure 1A, the 
mAb Croma-229 immunoprecipitated 48 kDa protein 
from lysates of infected cells that were labeled within 
first three hours after infection, indicating that the m06 
protein is synthesized very early in the infection. After 
that, gp48 was detected in similar quantity throughout 
the replication cycle of MCMV. Abundant cytoplasmic 
protein 14-3-3 θ served as a cellular control for compar-
ison of labeled material used for immunoprecipitation 
(Figure 1A, bottom). 
The expression pattern was determined by immu-
nofluorescence and confocal analysis. In the early phase 
of infection (up to 12 h p.i.), a majority of m06 protein 
was concentrated in pericentriolar tubulo-cysternal 
structures (Figure 1B, 8 h p.i.) representing the Golgi 
compartments, as verified by colocalization with a Gol-
gi marker (Figure 4), and in perinuclear vesicular struc
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tures (Figure 1B). In the late phase of infection (14–24 h 
p.i.), however, m06 protein was localized in enlarged 
tubulo-vacuolar structures that were dispersed through-
out the perinuclear area of the cell (Figure 1B), an area 
confined by the edges of microtubular network (data not 
shown). The pattern observed in the late-phase infected 
fibroblasts was not observed in NIH 3T3-m06 cell line 
(Figure 1C). In these cells the m06 expression pattern 
was similar to the early phase infected cells, indicating 
that MCMV gene products from the late phase contrib-
ute to the distribution pattern observed in late-phase 
infected fibroblasts. 
 
No Evidence for Cell Surface Expression of MCMV-
m06 Protein 
Given that the function of m06 protein in the secretory 
pathway is associated with MHC-I molecules and abol-
ishes their expression at the cell surface,3,5,6,30,31 we next 
examined whether m06 reaches the cell surface. Alt-
hough the cell surface Kd (Figure 2A) and Dd (data not 
shown) MHC-I proteins were almost completely down-
regulated at 8 h p.i., very little, if any, mAb Croma-229 
binding to the surface of infected cell was determined at 
8 h p.i. (Figure 2A) and at later times of infection (data 
not shown). At the same time, both Kd and m06 were 
determined inside the cell, by permeabilization and flow 
cytometric analysis (data not shown). 
Although, the flow cytometic analysis of surface 
expression is very sensitive method, many proteins that 
have a high turnover rate at the PM may escape detec-
tion. Thus we performed a more sensitive assay which is 
based on exposure of cells to mAb Croma-229 in cul-
ture medium. Even after 4 hours of exposure, no 
Croma-229 was detected inside the cells (Figure 2B, 
absence of green fluorescence), indicating that no m06 
protein was exposed at the PM to be captured by mAbs. 
Under the same conditions, transferrin receptor (TfR) 
and LAMP, two membrane proteins with high PM turn-
over that are rapidly internalized via clathrin-dependent 
route, were efficiently recognized by specific mAbs 
which concentrated in typical intracellular localization 
for these proteins, the pericentriolar and perinuclear 
tubulo-vesicular endosomes, respectively (Figure 2B, 
red fluorescence). The same was observed also in NIH 
3T3-m06 cells (data not shown). The fluid-phase uptake 
of mAbs was negligible, although another pathway  
of internalization which is responsible for the uptake  
of fluid-phase was functional in MCMV-infected cells, 
as demonstrated by the internalization of Alexa555-
cholera-toxin B-subunit (CTxB) (Figure 2B). 
 
Perinuclear Association of MCMV-m06 Protein with 
MHC-I Molecules of the Endosomal Pathway 
In uninfected fibroblasts, the steady-state staining pat-
tern of intracellular MHC-I proteins hardly distinguishes 
Figure 1. The expression kinetics and intracellular staining
pattern of MCMV-m06 protein. Expression kinetics (A). 
MEFs were infected with Δm138-MCMV and pulse-labeled
with [35S]methionine at indicated time post-infection. Lysates
were immunoprecipitated with the mAb Croma-229 (gp48, 
up) or with rabbit antiserum to the cellular protein 14-3-3θ
(bottom) and analyzed by reducing SDS-PAGE on 10 % gel.
Confocal images of the intracellular staining pattern of m06
protein in Δm138-MCMVinfected MEFs (B) and NIH 3T3-
m06 cells (C). Bars, 10 μm.  
 
Figure 2. MCMV m06 does not reach the cell surface. (A)
Cell surface expression. Flow cytometric profiles of cell sur-
face expression of Kd and MCMV-m06 protein in uninfected 
and Δm138-MCMV-infected (8 h p.i.) MEFs. (B)
Cointernalization of mAb captured cell surface proteins and 
m06. Confocal images of infected MEFs that were at 4 hours
p.i. incubated for additional four hours with mAb Croma-229 
(m06) and R17 (TfR), Alexa555-cholera-toxin B-subunit 
(CTxB) or LAMP. After internalization, the cells were fixed 
and internalized mAbs stained with Alexa488-anti mouse IgG1
(gp48/m06, green fluorescence), and Alexa555-anti rat IgG 
(TfR or LAMP, red fluorescence). Bars, 10 μm.  
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clear intracellular structures (data not shown), whereas 
in MCMV infected cells at 8 h p.i. the dense perinuclear 
accumulations of MHC-I proteins in vesicular and 
vesiculo-tubular structures were observed (Figure 3A).8 
These structures almost completely overlapped with the 
steady-state expression of m06 protein (Figure 3A), 
indicating that m06 protein also accumulates in the 
perinuclear retention endosomes of early phase infected 
cells.8 In the late phase (i.e. 24 h p.i.), the overall 
amount of intracellular MHC-I proteins was reduced, as 
a consequence of their degradation,8 although they were 
found in the clearly confined perinuclear vesicular 
structures (Figure 3A). In these structures, they colocal-
ized with m06 protein (Figure 3A), although a large 
amount of m06 protein was also found in tubulo-vacuolar 
structures that were MHC-I negative (Figure 3A). 
In order to distinguish whether m06 protein local-  
izes with MHC-I proteins in endosomes, we labeled cell 
surface Kd with mAbs at 4 h p.i. and internalized either 
4 hours (early phase of infection) or 20 hours (late phase 
of infection). As shown in Figure 3B, internalized Kd 
molecules were accumulated in the perinuclear endo-  
somes with predominant localization in the pericentrio-  
lar area of early-phase infected cells (Figure 3B, left) 
and cytoplasmic vacuoles of late-phase infected cells 
(Figure 3B, right). In these structures, internalized Kd 
colocalized with steady-state m06 protein (Figure 3B). 
Given that we labeled only cell surface Kd, we can con-  
clude that internalized Kd molecules meet with m06 
protein in endosomes. Although the pericentriolar ac-  
cumulation of internalized Kd and steady-state m06 was 
not observed at later times of infection (Figure 3B, 
right), internalized Kd molecules were loaded into a part 
of perinuclear tubulo-vacuolar endosomes containing 
m06 protein, indicating that these structures are accessi-  
ble to endocytosed cargo and, at least a part of them, 
may be of endosomal origin. 
 
MCMV-m06 Protein Accumulates in Early Endo-
somes of MCMV-infected Cells 
In order to clarify whether the m06 protein reaches early 
endosomal compartments, we labeled the cell surface 
cargo molecules of various endocytic pathways that 
upon endocytic uptake converge into early endosomes. 
MHC-I proteins using Arf6-associated endocytic 
route,15 transferrin receptor (TfR) using clathrin-
dependent route,14 and cholera-toxin B-subunit using 
cdc42-dependent endocytic route,32 were labeled at 4 h 
p.i., internalized for 4 hours (8 h p.i.) and colocalized 
with steady-state m06 protein (Figures 3B and 4A). 
After 4 hours of internalization, all three cargo proteins 
were retained in the perinuclear endosomal vesiculo-
tubular endosomes of MCMV-infected cells, including 
pericentriolar tubular endosomes (Figures 3B and 4A). 
In these endosomes they colocalized with the m06 pro-
tein (Figures 3B and 4A, inserts) suggesting that inter-
nalized cargo from the clathrin-dependent, Arf6-
associated and cdc42-dependent routes converge into 
early endosomal compartment that is loaded also with 
m06 protein. To further verify that pericentriolar endo-
somes which were loaded with m06 protein are of the 
endosomal origin, we treated the cells with brefeldin A 
(BFA), a chemical that disperses the Golgi compart-
ments and causes their fusion with ER.33 As expected, 
BFA treatment dispersed GS28-positive Golgi mem-
branes and pericentriolar m06-positive tubular mem-
branes, but not m06-positive vesicles (Figure 4B), indi-
cating that a part of the m06-loaded membranes is BFA-
resistant. These membranes were of early endosomal 
origin, since they remain associated with early endoso-
mal antigen 1 (EEA1) after BFA treatment (Figure 4B). 
In addition, perinuclear endosomes loaded with internal-
ized Kd, TfR and CTxB did not disperse after BFA-
 
Figure 3. MCMV-m06 protein co-localizes with endosomal 
MHC-I molecules. (A) Confocal images of simultaneously 
stained steady-state (ss) MCMV-m06 protein (gp48) and Kd at 
8 and 24 hours p.i. (B) Confocal images of internalized (i) Kd
and steady-state MCMV-m06 protein (gp48) at 8 and 24 hours 
p.i. Cell surface Kd molecules of Δm138-MCMV infected 
cells were labeled with mAb MA215 at 4 h p.i. (at 4 °C) fol-
lowed by 4 or 20 hours of internalization at 37 °C. Kd mole-
cules were visualized with Alexa555-anti mouse IgG2a (red 
fluorescence) and MCMV-m06 protein with Alexa488-anti-
mouse IgG1 (green fluorescence). Quantification of 
colocalization is based on Manders’ coefficients M1 (i.e. Kd
vs. m06) and M2 (i.e. m06 vs. Kd) representing the mean ± 
S.D. determined on sections of 5 cells from two independent 
experiments. Bars, 10 μm and 5 μm in inserts. 
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treatment and remain associated with m06 protein (Fig-
ure 4C). Taken together, this data indicates that pericen-
triolar tubular accumulation of m06 protein resembles 
its Golgi localization and that m06 protein accumulates 
in perinuclear endosomes but not in pericentriolar tubu-
lar recycling endosomes of MCMV infected cells. 
 
Early Endosomal Loading of the m06 Requires 
Other MCMV Proteins 
Given that the MCMV infection reorganizes early 
endosomal system of the cell and remodels endosomal 
routes,8 we next examined whether m06 protein distrib-
utes into early endosomes of NIH 3T3-m06 
transfectants, in the absence of other MCMV functions. 
In these cells most of m06 protein was found in the 
membranous structures in the pericentriolar area which 
was also crammed with GS28-positive Golgi mem-
branes (Figure 5A, left), and EEA1-positive (Figure 5A, 
middle) and TfR-loaded (Figure 5A, right) endosomes. 
Thus, the level of colocalization of m06 with these 
markers was rather high in untreated cells (Figure 5C). 
In order to distinguish in which membranous structure 
m06 proteins localize, we treated the cells with BFA in 
 
Figure 4. Localization of MCMV-m06 protein in early endosomes of Δm138-MCMV-infected cells. (A) Colocalization of
steady-state (ss) MCMV-m06 protein (gp48) with internalized transferrin receptor (TfR) and cholera-toxin B-subunit (CTxB).
Infected MEFs were at 4 hours p.i. incubated with mAbs to TfR (R17) or Alexa555-CTxB (at 4 °C). After 4 hours of internaliza-
tion at 37 °C, the cells were fixed and stained with mAb Croma-229 and Alexa488-anti-mouse IgG1 to visualize ss m06 and
Alexa555-anti-rat IgG to visualize internalized TfR. (B) Infected MEFs were untreated or brefeldin A (BFA) treated (10 μg/ml, 60
min) at 8 hours p.i. Confocal images of ss m06 (gp48) simultaneously stained with either the Golgi marker (GS28) or early
endosomal marker (EEA1). (C) Infected MEFs were at 4 h p.i. incubated with mAb MA-215, mAb R17 or Alexa555-CTxB (at 4
°C) and after four hours of internalization treated with 10 μg/ml of BFA for 60 min. Steady-state m06 protein and internalized cargo
molecules were visualized as described above. Quantification of colocalization is based on Manders’ coefficients M1 and M2 repre-
senting the mean ± S.D. determined on sections of 5 cells from two independent experiments. Bars, 10 μm and 5 μm in inserts. 
N. Kučić et al., Endosomal Retention of m06 Protein 219 
Croat. Chem. Acta 85 (2012) 213. 
concentration that dispersed Golgi in normal fibroblasts 
(Figure 4). As expected, BFA treatment dispersed the 
m06 protein together with the Golgi but a large fraction 
of m06 remained in the vesicular form (Figure 5B, left), 
indicating that it localized in a compartment which lacks 
capacity to fuse with membranes of the ER. BFA treat-
ment did not disperse EEA1- positive endosomes and 
TfR-loaded juxtanuclear endosomes which remained in 
the pericentriolar area (Figure 5B, middle and right), but 
dispersed the m06 protein into vesicles which were 
largely EEA1-negative (Figure 5B, middle) and TfR-
negative (Figure 5B, right). Altogether, this data indi-
cates that in the absence of other viral functions the m06 
protein localizes in the Golgi compartments and in 
perinuclear vesicular structures which are not early 
endosomes, suggesting that the m06 protein does not 




In this report we demonstrate that the MCMV-m06 
protein accumulates in the endosomal system of 
MCMV-infected cells together with internalized MHC-I 
proteins, clathrin-independent (TfR) and cdc42-depen-
dent (CTxB) cargo. 
The MCMV-m06 protein associates with nascent 
MHC-I proteins in the ER into relatively stable com-  
plex,5 which is transported into the Golgi and from this 
localization is rerouted towards late endosomes for 
degradation.5 This viral activity is combined with the 
effect of MCMV-m152 protein, which retains MHC-I 
proteins in the ER/ERGIC compartment,3,4 and the 
MCMV-m04 protein which associates with MHC-I 
proteins in the ER into the stable complex that reaches 
the cell surface.6 The consequence of the activity of 
m06 and m152 is prevented export of nascent MHC-I 
proteins to the cell surface and their loss,3,4 and the 
consequence of the activity of m04 is the export of 
masked MHC-I complexes with an important immuno-  
regulatory function.6,7 In addition to these viral func-  
tions which interfere with MHC-I trafficking in the 
secretory pathway, MCMV also encodes an early func-
tion that remodels the early endosomal system and early 
endosomal routes.8 This remodeling affects cell surface 
resident MHC-I proteins which are, upon constitutive 
endocytic uptake, retained in perinuclear vacuolar early 
endosomes and inhibited of entry into the recycling  
and degradative route.8 Similar mechanism of down-
regulation of cell surface MHC-I follows also HIV Nef.34 
We demonstrated the localization of m06 protein 
in early endosomes that collect internalized MHC-I 
 
Figure 5. Intracellular distribution of MCMV-m06 protein in the absence of other MCMV proteins. Co-distribution of steady-
state (ss) m06 protein (gp48) with ss GS28 (Golgi marker), ss EEA1 (early endosomal marker) and internalized (i) TfR in (A)
untreated and (B) brefeldin A (BFA)-treated (10 μg/ml, 60 min) NIH 3T3-m06 cells. (C) Quantitative analysis of colocalization
based on Manders’ coefficients. Data represent the mean ± S.D. 
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proteins, TfR and CTxB. It is well known that MHC-I 
molecules constitutively internalize via Arf6-associated 
endosomal route14,15,35 into nascent endocytic carriers 
free of clathrin-dependent cargo (i.e. TfR).14 These 
carriers fuse with the early acceptor compartment which 
collects nascent endocytic carriers derived in clathrin-
dependent route.14,15 Additionally, this compartment 
collects also endocytic carriers known as CLICs, which 
carry CTxB and dextran, in a phosphatydil-inositiol-3-
kinase (PI3K)-dependent manner.15 Thus, the early 
acceptor compartment represents "classical" early endo-
somes33 in which internalized MHC-I proteins, TfR and 
CTxB are mixed and transported towards the cell center. 
During transport in uninfected cells early endosomes 
mature. TfR and a fraction of MHC-I proteins are sorted 
into tubular recycling endosomes,28,35,36 the rest of 
MHC-I proteins into late endosomes and CTxB into the 
Golgi.37 In MCMV infected cells, however, the segrega-
tion into recycling and late endosomal route is inhibited, 
resulting in vacuolization of early endosomes and their 
arrest around the pericentiolar area, including retention 
of internalized cargo proteins.8 Given that the m06 pro-
tein was found together with internalized cargo from 
three different routes, we concluded that the m06 is 
capable of reaching early endosomes in MCMV infect-
ed cells. In contrast to MHC-I proteins and TfR, m06 
was dispersed from the pericentriolar tubular endosomes 
after BFA treatment (Figure 4), suggesting that m06 
does not enter into the recycling route but rather pro-
gresses towards late endosomes into the degradative 
route. In MCMV-infected cells, however, exit from 
early endosomes into the degradative route is slow,8 
resulting also in the retention of m06 protein. 
The data presented in this report, demonstrates 
that m06 protein does not reach the cell surface and that 
the MCMV effect on cell-surface and endosomal MHC-I 
is not associated with the activity of this protein. Nev-  
ertheless, m06 protein was found in the retention endo-  
somes. This indicates either that m06-MHC-I complex-  
es from the ER are transported from the Golgi into early 
endosomes prior to their entry into late endosomes, or 
that a fraction of the m06 protein not associating with 
nascent MHC-I proteins is rerouted from the trans-Golgi 
network into early endosomes. This pathway of the m06 
protein was not observed in NIH 3T3-m06 cells, a trans-
fectant cell line, suggesting that other viral functions 
rearrange the Golgi-endosomal route in MCMV infected 
cells (Figure 5). In the transfectant, m06 was retained 
outside the early endosomes, in a vacuolo-tubular com-
partment. The distribution pattern of this compartment, 
which occupies perinuclear area, disperses after BFA 
treatment and relies on the microtubular network, sug-
gests that it can be either of ERGIC or of late 
endosomal origin. Biochemical analysis revealed two 
populations of m06 expressed in the cell with different 
fate.26 Complexes of m06 with nascent MHC-I proteins 
are transported into lysosomes for degradation, whereas 
the unassembled m06 is degraded by cytosolic pro-
teasomes in the ER-associated degradation (ERAD).26 
Thus, it cannot be excluded that vacuolar accumulations 
of the m06 protein outside early endosomes of trans-
fected cells represent an excess of m06 which is unasso-
ciated with MHC-I and thereby cannot be rerouted into 
late endosomes but rather remains in the ER/ERGIC on 
its way towards proteasomal degradation. 
MCMV, like other members of the herpesvirus 
family, possess a large collection of genes that target 
almost every step of MHC-I biogenesis in the secretory 
pathway and their cell surface localization.38 In contrast, 
HIV-1 uses single early gene Nef to down-regulate 
MHC-I.39 According to the "signaling" model, Nef 
down-regulates MHC-I by multistep interaction with 
cellular proteins which leading to the recruitment of 
PI3K,40 a key regulator of endosomal shaping, and in-  
ternalization of MHC-I proteins through clathrin-  
independent Arf6-associated pathway.40,41,42 After inter-  
nalization, Nef sequesters MHC-I molecules into para-  
nuclear endosomes.40,41 In contrast, according to the 
"stoichiometric" model, Nef down-regulates MHC-I by 
diverting newly synthesized MHC-I to lysosomes by an 
M20- and AP1-dependent mechanism.43,44 In the recent 
report, Dikeakos et al. demonstrated that Nef orches-  
trates MHC-I down-regulation by sequential actions of 
the signaling mode followed by the stoichiometric 
mode.34 It appears that the similar sequence operates 
also in MCMV infected cells. Thus, the role of the m06 
protein in this sequence remains to be determined. 
 
CONCLUSION 
Summing up, we can conclude that the MCMV-m06 
protein reaches early endosomes of MCMV-infected 
cells without export to the cell surface. As such, m06 is 
not essential for accelerated down-regulation of cell 
surface resident MHC-I proteins in MCMV-infected 
cells. However, it appears that m06 associates with 
MHC-I in the retention endosomes formed by a separate 
viral function. The function of these endosomes remains 
to be elucidated. 
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